Eplerenone (Inspra®)

Following a resubmission

Eplerenone (Inspra) is accepted for use within NHS Scotland in addition to standard therapy including beta blockers, to reduce the risk of cardiovascular mortality and morbidity between 3-14 days after myocardial infarction (MI) in stable patients with left ventricular dysfunction (left ventricular ejection fraction 40%) and clinical evidence of heart failure.

Eplerenone is the second aldosterone antagonist marketed in the UK. It reduces all-cause mortality and cardiovascular-related mortality and hospitalisation in patients with left ventricular dysfunction and clinical evidence of heart failure after an MI. There are no data on its clinical and cost effectiveness in patients with chronic heart failure compared to the other aldosterone antagonist marketed in the UK, which reduces mortality and morbidity in patients with chronic heart failure and is considerably cheaper.